|
Post by mnholdem on Dec 7, 2019 23:17:00 GMT -5
|
|
|
Post by mytakeonit on Dec 7, 2019 23:36:39 GMT -5
Wow ! That means that we are way pass the Frankenstein era ... and into the Wineinstein era. That is amazing !!!
But, that's mytakeonit
|
|
|
Post by falconquest on Dec 8, 2019 6:24:41 GMT -5
kevinmik 12/6/19, 06:56 AM $MNKD Mike said during Piper Conference to expect within 3 to 5 years, Mannkind will be focused on Organ & Lungs that will include Diabetes and a Pulmonary Division including a commercial organization. He also suggested the remaining pipeline will shake out going forward ideally packaging out non-pulmonary disease drug candidates to one source (partner). It looks like United Therapeutic is going to play a major role in what Mannkind looks like within 3 to 5 years and we need to see how Mannkind will be structured. The fact Mike said within 3 to 5 years Mannkind will be focused on Organ & Lungs that will include Diabetes & a Pulmonary Division suggest a restructuring of the company is coming. David Kendal : former Lilly CMO, Cialis -inhaled Tadalafil James Shanon: former GSK CMO, Mnkd Board, Imitrex - inhaled Sumatriptans, Aloxi- inhaled Palonosetron CINV. These can be bundle-licensed to GSK. Focusing on Organ dovetails with UT’s Organ transplant roadmap. Ditto Pulmonary. This points to UT will likely take an equity stake in Mnkd after 12/27/19 to benefit from $3B NOL and avoid 1.6 Warrants dilution.Read more: mnkd.proboards.com/user/1882/recent#ixzz67RGoWqYFThis is the guy who for years was a shameless pumper on the Yahoo board. He is always clever by insinuating certain events "could" happen but of course none of them ever come true. Same here as he uses the word "points". That's an opinion of which I would give no credence. I can't believe anyone would reference this character here on proboards.
|
|
|
Post by golfeveryday on Dec 8, 2019 10:41:13 GMT -5
kevinmik 12/6/19, 06:56 AM $MNKD Mike said during Piper Conference to expect within 3 to 5 years, Mannkind will be focused on Organ & Lungs that will include Diabetes and a Pulmonary Division including a commercial organization. He also suggested the remaining pipeline will shake out going forward ideally packaging out non-pulmonary disease drug candidates to one source (partner). It looks like United Therapeutic is going to play a major role in what Mannkind looks like within 3 to 5 years and we need to see how Mannkind will be structured. The fact Mike said within 3 to 5 years Mannkind will be focused on Organ & Lungs that will include Diabetes & a Pulmonary Division suggest a restructuring of the company is coming. David Kendal : former Lilly CMO, Cialis -inhaled Tadalafil James Shanon: former GSK CMO, Mnkd Board, Imitrex - inhaled Sumatriptans, Aloxi- inhaled Palonosetron CINV. These can be bundle-licensed to GSK. Focusing on Organ dovetails with UT’s Organ transplant roadmap. Ditto Pulmonary. This points to UT will likely take an equity stake in Mnkd after 12/27/19 to benefit from $3B NOL and avoid 1.6 Warrants dilution.Read more: mnkd.proboards.com/user/1882/recent#ixzz67RGoWqYFThis is the guy who for years was a shameless pumper on the Yahoo board. He is always clever by insinuating certain events "could" happen but of course none of them ever come true. Same here as he uses the word "points". That's an opinion of which I would give no credence. I can't believe anyone would reference this character here on proboards. this comment from ‘Lakers’ is not too far fetched in my opinion. In the TrepT agreement, UTHR said they would be responsible for long term manufacturing of the product...
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 8, 2019 11:43:58 GMT -5
This is the guy who for years was a shameless pumper on the Yahoo board. He is always clever by insinuating certain events "could" happen but of course none of them ever come true. Same here as he uses the word "points". That's an opinion of which I would give no credence. I can't believe anyone would reference this character here on proboards. this comment from ‘Lakers’ is not too far fetched in my opinion. In the TrepT agreement, UTHR said they would be responsible for long term manufacturing of the product... Actually if I take a snipet of your comments....I can see UTHR making an investment in MNKD to be the contract manufacturer of TreT and future products. Why would UTHR be bogged down with making it when MNKD has the expertise? So UTHR would put up the money and have MNKD manufacture TreT. I'm not expecting a stake in MNKD until TreT is approved which means hopefully the stock price will be higher and Mike can use the 23M Warrants that will not be exercised on Dec. 26th. 23M shares equates to a ~10% Equity position. If the SP is $10 that means a $200MM cash into MNKD. It's plausible.
|
|
|
Post by mnholdem on Dec 8, 2019 11:58:02 GMT -5
If UT becomes the majority SH of a future profitable Mnkd who pays no tax for a foreseeable future due to $3B NOL, Ops margin becomes pure profit margin. Furthermore, UT could potentially give generous mfgr and R&D contracts to Mnkd to make MNKD more profitable while not paying tax, maybe dividend. Even SO saw it too. He said UT could buy in phases to take advantage of $3B NOL. Once UT becomes majority SH, UT and Mnkd’s interest align. UT would want to make Mnkd tax free profitable. Mnkd would become an outsourced R&D and mfgr arm of UT plus tax free royalty - a legal non-Bermuda tax shelter for both companies. You can ask if the future Mnkd Director, mnholdem, likes the idea such as how much % for the initial stake, valuation, 2nd stake, 2nd valuation, the trigger. Let’s start the mock interview before he becomes the official Director, then can’t say much. It’s a golden opps to pick his brain as he can freely talk now. Mnholdem’s chance of being elected is high as I believe Thompson will certify 5%, then he will get more than enough vote. I’d treat Mnholdem as Director elected now. Pick his brain everyone for all biz matter. I still believe UT may likely take the initial stake before next May ASH meeting, before the new slate of Directors getting elected when it will be harder to get a unanimous approval and valuation will be higher. This is a somewhat tricky question to answer, primarily because in 2017 the IRS made changes related to Section 382 and the handling of NOLs under Section 172 in regard to change of ownership after an owner/equity structure shift. After an acquisition, say of MannKind for example, Section 382 will limit the amount of MannKind NOLs available to offset future taxable income. Also, CEO Castagna and CFO Binder secured the current MidCap financing with valuable IP, so MannKind NOLS could be subject to additional limitations caused by early ownership changes incurred during rounds of financing. It's complicated but the new code basically states the following: Section 382 Limitation
After an ownership change, the new loss corporation may only deduct its pre-change losses against taxable income in an amount equal to the Sec. 382 limitation amount. There are now three components or attributes to the Sec. 382 limitation as a result of the TCJA:
1. Base limitation, which is driven by the value of the stock
2. Built-in gain/loss, which is driven by the value of the assets, and
3. Disallowed interest expense that exceeds the limits ascribed in Section 163(j). Notice 2010-50
For Sec. 382 purposes any change in proportionate ownership which is attributable solely to fluctuations in relative FMVs of different classes of stock will not be taken into account. Under Notice 2010-50, the IRS will not challenge the reasonable application of the following two methods as long as either is applied consistently:
1. Full Value Methodology, in which the determination of the percentage of stock owned by any person is made on the basis of the relative fair market value of the stock owned by such person to the total fair market value of the outstanding stock of the corporation, or
2. Hold Constant Principal, in which the value of a share, relative to the value of all other stock of the corporation, is established on the date that share is acquired by a particular shareholder.
Changes to Section 172
Subsequent to the enactment of TCJA, the NOL deduction for a tax year is equal to the lesser of:
1. The aggregate of the NOL carryover to such year, plus the NOL carrybacks to such year, or
2. 80 percent of taxable income (determined without regard to the deduction.)
Generally, NOLs can no longer be carried back but are now allowed to be carried forward indefinitely. Prior tax law generally allowed for a carryback of NOLs for two years and a carryforward of NOLs for 20 years. The change to Sec. 172 will impact the valuations of NOL benefits for both tax and financial reporting purposes going forward.
--- I'm not dodging your question. I'm simply pointing out that the the NOL issue can be complicated. MannKind should definitely be assessing all business opportunities and evaluating their financial impacts - positive and negative. I wouldn't be too eager to give away long-term assets for short-term benefits.
|
|
|
Post by ktim on Dec 8, 2019 13:36:58 GMT -5
Yes, I've been aware of that as I follow UTHR. But the post I was inquiring about was about Mike's presentation and MNKD, correct? MNKD has no involvement in that transplant work at UTHR.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 8, 2019 13:56:54 GMT -5
Yes, I've been aware of that as I follow UTHR. But the post I was inquiring about was about Mike's presentation and MNKD, correct? MNKD has no involvement in that transplant work at UTHR. I didn't hear anything pertaining to the organ division but that's not to say it didn't happen. The audio was poor BUT I can see a pathway for MNKD/UTHR to use TS for new therapies associated with new organs. I'm sure new medications will be needed to accept the new organs.
|
|
|
Post by ktim on Dec 8, 2019 14:05:02 GMT -5
Yes, I've been aware of that as I follow UTHR. But the post I was inquiring about was about Mike's presentation and MNKD, correct? MNKD has no involvement in that transplant work at UTHR. I didn't hear anything pertaining to the organ division but that's not to say it didn't happen. The audio was poor BUT I can see a pathway for MNKD/UTHR to use TS for new therapies associated with new organs. I'm sure new medications will be needed to accept the new organs. I suppose that could be said about most any drug currently made or in the future that one could see a technical pathway to a TS version. TS is quite versatile. That doesn't mean there is a reason why it would provide any benefit. It's not as if the immunosuppressive drugs used with transplants need fast absorption. Why are you sure that current drugs used with transplant patients wouldn't work with these new sources of organs? Is that something UTHR has talked about, or you've seen in papers from them?
|
|